FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.

Minlin JiangChunyan WuLiping ZhangChenglong SunHao WangYi XuHui SunJun ZhuWencheng ZhaoQiyu FangJia YuPeixin ChenShengyu WuZixuan ZhengYayi He Cai-Cun Zhou

Published in: Journal for immunotherapy of cancer (2022)

FOXP3 interacts closely with immune biomarkers on tumor-infiltrating cells in TME. This study highlighted the crucial prognostic value and promising clinical applications of FOXP3 in SCLC.

Keyphrases

regulatory t cells
small cell lung cancer
induced apoptosis
dendritic cells
cell cycle arrest
oxidative stress
immune response